Mr. Andre Larente reports

DIAGNOS ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Diagnos Inc. has closed a first tranche of 1,125,000 units issued at a price of 28 cents per unit, for gross proceeds of $315,000, as part of a non-brokered private placement of up to 5,357,142 units, for gross proceeds of up to $1.5-million. The corporation expects to close a second and final tranche of the private placement before May 31, 2024.

Each unit consists of:

• One common share;
• One common share warrant.

As part of the closing of the first tranche of the private placement, 1,125,000 warrants have been issued to the subscribers. Each warrant can be exercised to purchase one share at a price of 40 cents per share for a period of 18 months ending Nov. 9, 2025.

The net proceeds from the private placement will be used to finance product development and commercialization of artificial-intelligence-based screening services, as well as general and administrative operations.

All securities issued as part of the first tranche of the private placement are subject to a statutory hold period ending Sept. 10, 2024.

The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.

All moneys quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (computer assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.